Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Annette Reichardt; Barbara Hermes; Jochen Schuette; Silke Cameron; Peter Hohenberger; Philipp J. Jost; Salah-Eddin Al-Batran; Lars H. Lindner; Sebastian Bauer; Eva Wardelmann; Bengt Nilsson; Raija Kallio; Panu Jaakkola; Jouni Junnila; Thor Alvegard; Peter Reichardt

doi:10.1001/jamaoncol.2020.2091

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Barbara Hermes, Jochen Schuette, Silke Cameron, Peter Hohenberger, Philipp J. Jost, Salah-Eddin Al-Batran, Lars H. Lindner, Sebastian Bauer, Eva Wardelmann, Bengt Nilsson, Raija Kallio, Panu Jaakkola, Jouni Junnila, Thor Alvegard, Peter Reichardt

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	JAMA Oncology
Vuosikerta	6
Numero	8
Sivut	1241-1246
Sivumäärä	6
ISSN	2374-2437
DOI - pysyväislinkit	https://doi.org/10.1001/jamaoncol.2020.2091
Tila	Julkaistu - elok. 2020
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3122 Syöpätaudit

Pääsy asiakirjaan

10.1001/jamaoncol.2020.2091

Siteeraa tätä

Joensuu, H., Eriksson, M., Hall, K. S., Reichardt, A., Hermes, B., Schuette, J., Cameron, S., Hohenberger, P., Jost, P. J., Al-Batran, S-E., Lindner, L. H., Bauer, S., Wardelmann, E., Nilsson, B., Kallio, R., Jaakkola, P., Junnila, J., Alvegard, T., & Reichardt, P. (2020). Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. JAMA Oncology, 6(8), 1241-1246. https://doi.org/10.1001/jamaoncol.2020.2091

@article{b572e731a0c24010a5434856aec284c1,

title = "Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up",

keywords = "MESYLATE, FAILURE, 3122 Cancers",

author = "Heikki Joensuu and Mikael Eriksson and Hall, {Kirsten Sundby} and Annette Reichardt and Barbara Hermes and Jochen Schuette and Silke Cameron and Peter Hohenberger and Jost, {Philipp J.} and Salah-Eddin Al-Batran and Lindner, {Lars H.} and Sebastian Bauer and Eva Wardelmann and Bengt Nilsson and Raija Kallio and Panu Jaakkola and Jouni Junnila and Thor Alvegard and Peter Reichardt",

year = "2020",

month = aug,

doi = "10.1001/jamaoncol.2020.2091",

language = "English",

volume = "6",

pages = "1241--1246",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "8",

}

Joensuu, H, Eriksson, M, Hall, KS, Reichardt, A, Hermes, B, Schuette, J, Cameron, S, Hohenberger, P, Jost, PJ, Al-Batran, S-E, Lindner, LH, Bauer, S, Wardelmann, E, Nilsson, B, Kallio, R, Jaakkola, P, Junnila, J, Alvegard, T & Reichardt, P 2020, 'Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up', JAMA Oncology, Vuosikerta 6, Nro 8, Sivut 1241-1246. https://doi.org/10.1001/jamaoncol.2020.2091

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. / Joensuu, Heikki; Eriksson, Mikael; Hall, Kirsten Sundby et al.

julkaisussa: JAMA Oncology, Vuosikerta 6, Nro 8, 08.2020, s. 1241-1246.

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

TY - JOUR

T1 - Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors An Analysis of a Randomized Clinical Trial After 10-Year Follow-up

AU - Joensuu, Heikki

AU - Eriksson, Mikael

AU - Hall, Kirsten Sundby

AU - Reichardt, Annette

AU - Hermes, Barbara

AU - Schuette, Jochen

AU - Cameron, Silke

AU - Hohenberger, Peter

AU - Jost, Philipp J.

AU - Al-Batran, Salah-Eddin

AU - Lindner, Lars H.

AU - Bauer, Sebastian

AU - Wardelmann, Eva

AU - Nilsson, Bengt

AU - Kallio, Raija

AU - Jaakkola, Panu

AU - Junnila, Jouni

AU - Alvegard, Thor

AU - Reichardt, Peter

PY - 2020/8

Y1 - 2020/8

KW - MESYLATE

KW - FAILURE

KW - 3122 Cancers

U2 - 10.1001/jamaoncol.2020.2091

DO - 10.1001/jamaoncol.2020.2091

M3 - Article

VL - 6

SP - 1241

EP - 1246

JO - JAMA Oncology

JF - JAMA Oncology

SN - 2374-2437

IS - 8

ER -